Droxidopa for Menkes Disease

This trial explores a treatment called Northera (Droxidopa) for children with Menkes disease who experience symptoms like dizziness and low blood pressure when standing. The trial aims to determine if Droxidopa can safely improve these symptoms and enhance quality of life. Participants should be children or teens aged 7 to 17 with Menkes disease who have experienced dizziness or bowel issues for more than four weeks. As a Phase 1/Phase 2 trial, this research focuses on understanding how the treatment works and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to important medical advancements.

Yes, you will need to stop taking certain medications, including any alpha-1 adrenoreceptor agonist, beta-blocker, DOPA decarboxylase inhibitor, midodrine, ephedrine, or any triptan medication.

Research has shown that Northera (Droxidopa) has been tested for safety in people with conditions similar to Menkes disease. In these studies, patients reported improvements in symptoms such as dizziness, lightheadedness, and feeling faint, suggesting that Droxidopa is generally well-tolerated.

Additionally, the FDA has already approved Droxidopa for treating certain symptoms in another condition, indicating it has passed safety checks for that use and providing some reassurance about its safety.

Droxidopa is unique because it targets norepinephrine deficiency, which is a key issue in Menkes disease. Unlike the standard of care that primarily focuses on managing symptoms with copper injections, droxidopa aims to address the underlying biochemical imbalance by boosting norepinephrine levels. Researchers are excited about this treatment because it offers a new mechanism of action that could improve neurological function and overall quality of life for patients with Menkes disease.

Research shows that Droxidopa, which participants in this trial may receive, can help treat symptoms of dysautonomia, such as dizziness and low blood pressure, in patients with conditions like Menkes disease. Studies involving adults and young adults with dysautonomia, a condition affecting the nervous system, have found that Droxidopa can improve symptoms like fainting and a drop in blood pressure when standing up. Droxidopa increases norepinephrine, a chemical that helps control blood pressure and is often low in people with dysautonomia. Early findings suggest that Droxidopa can raise blood pressure and improve quality of life. Although limited research exists on children with Menkes disease, the drug's mechanism offers hope for improving symptoms in this group.¹²³⁴⁵